What is ANZUP?
Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group is a charity that conducts clinical trials research to improve treatment of bladder, kidney, testicular, penile and prostate cancers.
This group of cancers are called urogenital cancers, but we refer to them as below the belt cancers.
ANZUP brings together a leading multi-disciplinary network of oncology, surgical, medical, radiation, nursing, psychology and allied health professionals from within the urogenital cancer field to conduct vital research through clinical trials. ANZUP’s members are committed to improving outcomes for those affected by these ‘below the belt’ cancers.
Below the Belt fundraises to support ANZUP cancer research.
Every year, approximately 27,224 new cases of below the belt cancers are diagnosed in Australia and 4,502 in New Zealand – that’s 77 people every day.
It can be challenging to obtain the initial funding required to move a concept through to being a viable clinical trial. That’s why the ANZUP Below the Belt Research Fund was established to help great ideas develop further. Any investment goes directly to the Belt the Belt Research Fund to support ANZUP trials to improve outcomes for people with below the belt cancers.
We need your help to fund more trials.
Help ANZUP conduct future below the belt cancer research by participating in a Below the Belt Challenge today or by making a donation.
Since 2015, Below the Belt has raised over $1.94 million for cancer research.
All of the major milestones in controlling cancer worldwide have come through clinical trials, but we still have a long way to go to help every person affected, at risk or diagnosed with this disease. Our Below the Belt Research Fund has helped our clinicians kick start new trial ideas. To date, seed funding has been awarded to 24 ANZUP members to help gather the evidence needed to develop full scale clinical research studies.
Previous successful trial ideas include
pathways to assist informed decision making;
a pilot of personalised hormone treatment for men with prostate cancer;
assessing the potential benefit in reducing recurrence of bladder cancer by irrigation with water after the cancer has been removed; and
an app for patients to record their symptoms in real time for review at their clinic visits; to name a few.